CHAIN Biotechnology is a biotechnology company using microbial technologies to develop healthcare products that is headquartered in Marlow, United Kingdom and was founded in 2014 by Basil Omar and Edward Green.
CHAIN’s Clostridium Assisted Drug Delivery (CADD) platform is an engineered strain of Clostridium bacteria that functions as a delivery vehicle for therapeutics. Engineered strains are manufactured in the form of spores and taken as tablets. The spores tolerate stomach acid and acid they germinate the colon the cells proliferate and release a bioactive molecule. CHAIN has other products in development aimed at treating infection, inflammation and metabolic disorders.
CHAIN’s treatment for Ulcerative Colitis and Crohn’s Disease has been completed pre-clnical testing. Scaling up the manufacturing of the Clostridial spore-based medicines following good manufacturing practice (GMP) will be aided by Porton Biopharma and Scitech. Other products in development focus on treating infection, inflammation and metabolic disorders.
On September 12, 2017 CHAIN Biotechnology received a grant worth £500,000 from Innovative UK.
Dr. Edward M. Green
Mr. Basil Omar
Founder, Chief Commercial Officer
Mr. Robert James Rickman
Chairman of Management Board
Biotech Focus: Interview with Dr Edward Green, CHAIN Biotechnology - Microbiome Times Magazine
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Synthetic biologyInterdisciplinary branch of biology and engineering, applying multiple disciplines to build artificial biological systems for research, engineering, and medical applications.
- MicrobiomeThe collective microorganisms and their genomic elements and interactions in a particular environment.